Efficacy and safety of alirocumab in patients with established atherosclerotic vascular disease before the first cardiovascular event: Pooled analysis of phase 3 ODYSSEY studies
Among patients with ASCVD without previous ACS or stroke, alirocumab significantly reduced calculated LDL-C levels vs controls and was well tolerated.
Authors
- Deepak L. Bhatt (ORCID: https://orcid.org/0000-0002-1278-6245)
- José Tuñón (ORCID: https://orcid.org/0000-0002-1373-0999)
- Hagai Tavori (ORCID: https://orcid.org/0000-0001-7553-9543)
- Michal Vráblík (ORCID: https://orcid.org/0000-0002-7226-1926)
- Pasquale Perrone Filardi (ORCID: https://orcid.org/0000-0002-3663-0931)
- Manuel Castro Cabezas (ORCID: https://orcid.org/0009-0009-5164-2082)
- Nikolaus Marx
- Mattéa Orsini
- Lâle Tokgözoğlu
Institutions
- SANE Mental Health Charity (GB)
- Charles University (CZ)
- Sint Franciscus Gasthuis (NL)
- Mount Sinai Hospital (US)
- CIEP (FR)
- Federico II University Hospital (IT)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Westfälische Hochschule (DE)
- General University Hospital in Prague (CZ)
- Hacettepe University (TR)
Publication Details
- Journal
- Journal of clinical lipidology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1016/j.jacl.2025.10.062
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00